Ultragenyx Pharmaceutical | RARE - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Immunic USD 23.33M 2.67M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Kyowa Hakko Kirin JPY 108.95B 75M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03